Azitra to Present Phase 1b and Phase 1/2 Trial Updates at BIO Summit
Azitra will present at the BIO Investment and Growth Summit on March 2 in Miami Beach, delineating the Phase 1b ATR-12 trial for Netherton syndrome, the Phase 1/2 ATR-04 program for EGFRi-associated dermal toxicity and IND-enabling studies for ATR-01 targeting ichthyosis vulgaris. Management will conduct one-on-one investor meetings.
1. Summit Presentation Details
Azitra will present at the BIO Investment and Growth Summit on March 2, 2026, at 2:15 PM ET in Ballroom 2C of the Eden Roc Miami Beach Hotel. Travis Whitfill, COO, and the management team will outline the company’s clinical pipeline and strategic milestones for investors and partners.
2. ATR-12 Phase 1b Trial Progress
The ATR-12 program is in a Phase 1b clinical trial in adult patients with Netherton syndrome, a rare chronic skin disease. The presentation will cover dosing progress, safety data, and preliminary efficacy signals for this first-in-human live biotherapeutic candidate.
3. ATR-04 Phase 1/2 Program Development
ATR-04, targeting moderate to severe EGFRi-associated dermal toxicity, has Fast Track designation from the FDA and an open IND. Management will discuss trial design, expected enrollment timelines, and potential impact on the estimated 150,000 U.S. patients affected by EGFRi-associated rash.
4. ATR-01 and Investor Engagement
ATR-01, aimed at treating ichthyosis vulgaris, is advancing through IND-enabling studies and will be highlighted to showcase its pipeline depth. One-on-one meetings with investors and potential partners will focus on Azitra’s clinical development strategy and corporate achievements.